Novo Nordisk and United Laboratories announced positive interim results from a Phase 2 clinical trial of UBT251, a triple agonist drug candidate designed to treat obesity in Chinese patients. The trial demonstrated a 19.7% reduction in body weight among study participants, marking a significant efficacy benchmark for the experimental treatment in this patient population.
The announcement comes as Novo Nordisk navigates a challenging period following disappointing results from its REDEFINE 4 trial. That study showed CagriSema, the company's dual agonist candidate, failed to meet its primary endpoint of demonstrating non-inferiority compared to Eli Lilly's tirzepatide, a competitive setback that contributed to recent declines in the company's stock valuation.
The UBT251 results represent an important development in Novo Nordisk's obesity pipeline and underscore the company's commitment to advancing multiple treatment options. The triple agonist mechanism of UBT251 targets three distinct pathways implicated in weight regulation, differentiating it from existing single and dual agonist therapies currently available in the market.